BioSpace News Archive

Rivus Pharmaceuticals Inc. today announced the completion of enrollment in its Phase 2a HuMAIN trial of HU6, an investigational controlled metabolic accelerator (CMA), in patients with the obese phenotype of heart failure with preserved ejection fraction (HFpEF).

Bexion Pharmaceuticals, Inc. announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023 , on Wednesday, January 31, 2024 , at 8:00 a.m. ET.

AIVITA Biomedical, Inc. today announced that chief executive officer Hans S. Keirstead, Ph.D. will present at Biotech Showcase 2024, taking place January 8-10 in San Francisco, California.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 5,800 shares of Curis common stock to a new employee.

GlycoEra AG today announced the expansion of its Series A financing with an investment from Bristol Myers Squibb (BMS).

MAPS Public Benefit Corp (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing. MAPS PBC raised more than $100 million including conversion of previously issued convertible notes.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company’s four pillars and outlook for 2024.

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake.

Vico Therapeutics B.V. announced a $60 million Series B financing.